These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
772 related articles for article (PubMed ID: 28780930)
1. Repurposing Drugs in Oncology: Next Steps. Verbaanderd C; Meheus L; Huys I; Pantziarka P Trends Cancer; 2017 Aug; 3(8):543-546. PubMed ID: 28780930 [TBL] [Abstract][Full Text] [Related]
2. Oncology pharmaceutical funding in New Zealand: a different approach and a proposal. Beatty PA; Laking GR J Oncol Pract; 2015 May; 11(3):249-51. PubMed ID: 25829524 [No Abstract] [Full Text] [Related]
3. Revisiting Repurposing. Sharlow ER Assay Drug Dev Technol; 2016 Dec; 14(10):554-556. PubMed ID: 27982703 [TBL] [Abstract][Full Text] [Related]
4. Creating New Economic Incentives for Repurposing Generic Drugs for Unsolved Diseases Using Social Finance. Bloom BE Assay Drug Dev Technol; 2015 Dec; 13(10):606-11. PubMed ID: 26284286 [TBL] [Abstract][Full Text] [Related]
5. Repurposing drugs in oncology: From candidate selection to clinical adoption. Pantziarka P; Verbaanderd C; Huys I; Bouche G; Meheus L Semin Cancer Biol; 2021 Jan; 68():186-191. PubMed ID: 31982510 [TBL] [Abstract][Full Text] [Related]
6. In Silico Oncology Drug Repositioning and Polypharmacology. Cheng F Methods Mol Biol; 2019; 1878():243-261. PubMed ID: 30378081 [TBL] [Abstract][Full Text] [Related]
7. Creating a unique, multi-stakeholder Paediatric Oncology Platform to improve drug development for children and adolescents with cancer. Vassal G; Rousseau R; Blanc P; Moreno L; Bode G; Schwoch S; Schrappe M; Skolnik J; Bergman L; Bradley-Garelik MB; Saha V; Pearson A; Zwierzina H Eur J Cancer; 2015 Jan; 51(2):218-24. PubMed ID: 25434924 [TBL] [Abstract][Full Text] [Related]
8. American Society of Clinical Oncology Position Statement on Addressing the Affordability of Cancer Drugs. American Society of Clinical Oncology J Oncol Pract; 2018 Mar; 14(3):187-192. PubMed ID: 29091534 [No Abstract] [Full Text] [Related]
9. Oncology business development global summit. Bockman JM; Nalam S IDrugs; 2005 Jan; 8(1):37-40. PubMed ID: 15650940 [No Abstract] [Full Text] [Related]
10. An Oncologist's Letter to Santa: Bring Me Drugs! Tempero M J Natl Compr Canc Netw; 2018 Dec; 16(12):1411. PubMed ID: 30545986 [No Abstract] [Full Text] [Related]
11. Pricing increases for cancer drugs sparks investigation. Venkatesan P Lancet Oncol; 2017 Jul; 18(7):e372. PubMed ID: 28552213 [No Abstract] [Full Text] [Related]
12. Policy Statement on the 340B Drug Pricing Program by the American Society of Clinical Oncology. American Society of Clinical Oncology J Oncol Pract; 2014 Jul; 10(4):259-63. PubMed ID: 24737877 [No Abstract] [Full Text] [Related]
13. Drug repurposing for cancer therapy, easier said than done. Gonzalez-Fierro A; Dueñas-González A Semin Cancer Biol; 2021 Jan; 68():123-131. PubMed ID: 31877340 [TBL] [Abstract][Full Text] [Related]
14. Drug rediscovery to prevent off-label prescription reduces health care costs: the case of tioguanine in the Netherlands. Mulder CJ; van Asseldonk DP; de Boer NK J Gastrointestin Liver Dis; 2014 Jun; 23(2):123-5. PubMed ID: 24949602 [No Abstract] [Full Text] [Related]
15. Genomics-enabled drug repositioning and repurposing: insights from an IOM Roundtable activity. Power A; Berger AC; Ginsburg GS JAMA; 2014 May; 311(20):2063-4. PubMed ID: 24867009 [No Abstract] [Full Text] [Related]
16. Can you teach old drugs new tricks? Nosengo N Nature; 2016 Jun; 534(7607):314-6. PubMed ID: 27306171 [No Abstract] [Full Text] [Related]
17. Clinical Trials and Therapeutic Rationale for Drug Repurposing in Schizophrenia. Lago SG; Bahn S ACS Chem Neurosci; 2019 Jan; 10(1):58-78. PubMed ID: 29944339 [TBL] [Abstract][Full Text] [Related]
18. Drug Repurposing for Cancer Therapy in the Era of Precision Medicine. K W To K; Cho WCS Curr Mol Pharmacol; 2022; 15(7):895-903. PubMed ID: 35156588 [TBL] [Abstract][Full Text] [Related]
19. Precision medicine and oncology: an overview of the opportunities presented by next-generation sequencing and big data and the challenges posed to conventional drug development and regulatory approval pathways. Doherty M; Metcalfe T; Guardino E; Peters E; Ramage L Ann Oncol; 2016 Aug; 27(8):1644-6. PubMed ID: 27117532 [No Abstract] [Full Text] [Related]
20. Prioritization of candidate cancer drugs based on a drug functional similarity network constructed by integrating pathway activities and drug activities. Di J; Zheng B; Kong Q; Jiang Y; Liu S; Yang Y; Han X; Sheng Y; Zhang Y; Cheng L; Han J Mol Oncol; 2019 Oct; 13(10):2259-2277. PubMed ID: 31408580 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]